(Total Views: 794)
Posted On: 07/11/2020 8:29:54 PM
Post# of 154883
The excerpt from the Cytodyn website does not explain if the results are monotherapy or combo therapy.
Those results sound like they are for the monotherapy trial, but phase 3 completed?
I understood the slide with 30 or 40 patients on it showing viral suppression out to 48 weeks to be monotherapy.
I understood the slide with 30 or 40 patients on it to show that when ART standard of care was interrupted, then leronlimab was able to maintain viral suppression without any help from the ART standard of care.
I thinik that slide was monotherapy but I don't know.
The July 9 data seems very impressive. I wonder why Lalezari has not commented on this dataset. HIV is his bread and butter.
Those results sound like they are for the monotherapy trial, but phase 3 completed?
I understood the slide with 30 or 40 patients on it showing viral suppression out to 48 weeks to be monotherapy.
I understood the slide with 30 or 40 patients on it to show that when ART standard of care was interrupted, then leronlimab was able to maintain viral suppression without any help from the ART standard of care.
I thinik that slide was monotherapy but I don't know.
The July 9 data seems very impressive. I wonder why Lalezari has not commented on this dataset. HIV is his bread and butter.
(1)
(0)
